论文部分内容阅读
目的分析硫酸镁联合复方异丙托溴铵雾化吸入治疗小儿哮喘的临床效果。方法选择2013年6月—2015年6月本院诊治的68例哮喘患儿作为研究对象,随机分为对照组30例和研究组38例。对照组行复方异丙托溴铵雾化吸入治疗,研究组给予硫酸镁联合复方异丙托溴铵雾化吸入治疗。对比两组咳嗽、哮鸣音等临床症状消失时间,FVC、FEV1等肺功能指标水平及不良反应发生情况。计量资料组间比较采用t检验,组内比较采用配对t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果研究组咳嗽消失时间、哮鸣音消失时间、湿啰音消失时间、呼吸恢复正常时间分别为(2.61±1.04)、(2.64±1.07)、(4.12±1.31)、(2.31±1.22)d,均短于对照组的(4.22±1.27)、(5.92±1.28)、(6.74±1.33)、(3.75±1.34)d,差异均有统计学意义(均P<0.05)。研究组与对照组治疗后FVC、FEV1、PEF分别为(0.89±0.04)、(0.94±0.03)L、(94.14±1.14)%、(0.67±0.02)、(0.71±0.02)L、(88.52±3.14)%,均较治疗前的(0.54±0.02)、(0.61±0.04)L、(59.62±1.87)%、(0.54±0.03)、(0.62±0.04)L、(58.96±1.08)%明显改善,差异均有统计学意义(均P<0.05)。两组治疗后各肺功能指标比较差异均有统计学意义(均P<0.05)。结论应用硫酸镁联合复方异丙托溴铵雾化吸入治疗小儿哮喘临床效果明显,可显著改善患儿肺功能,具有临床应用价值。
Objective To analyze the clinical effect of magnesium sulfate combined with ipratropium bromide atomizing inhalation on pediatric asthma. Methods Sixty-eight children with asthma diagnosed and treated in our hospital from June 2013 to June 2015 were randomly divided into control group (n = 30) and study group (n = 38). The control group received ipratropium bromide inhalation therapy, the study group was given magnesium sulfate combined with ipratropium bromide inhalation therapy. Comparing two groups of cough, wheeze and other clinical symptoms disappear time, FVC, FEV1 and other indicators of pulmonary function and adverse reactions. Measurement data were compared between groups using t test, the group was compared using paired t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The duration of cough disappearance, the time of wheeze disappearing, the duration of wet rales disappearing and resuming normal time were (2.61 ± 1.04), (2.64 ± 1.07), (4.12 ± 1.31) and (2.31 ± 1.22) d respectively in study group, (4.22 ± 1.27), (5.92 ± 1.28), (6.74 ± 1.33) and (3.75 ± 1.34) d respectively in the control group. The difference was statistically significant (all P <0.05). The FVC, FEV1 and PEF in study group and control group were (0.89 ± 0.04), (0.94 ± 0.03) L, (94.14 ± 1.14)%, (0.67 ± 0.02), (0.71 ± 0.02) L, (88.52 ± 3.14%) were significantly improved compared with those before treatment (0.54 ± 0.02), (0.61 ± 0.04) L, (59.62 ± 1.87)%, (0.54 ± 0.03), (0.62 ± 0.04) L and (58.96 ± 1.08)% respectively , The differences were statistically significant (all P <0.05). After treatment, the pulmonary function indexes of the two groups were significantly different (all P <0.05). Conclusion The application of magnesium sulfate combined with ipratropium bromide atomization inhalation treatment of pediatric asthma clinical effect is obvious, can significantly improve children’s lung function, with clinical value.